- Home
- CUBI vs NVAX Comparison
CUBI vs NVAX Comparison
Compare CUBI & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUBI
- NVAX
- Stock Information
- Founded
- CUBI 1994
- NVAX 1987
- Country
- CUBI United States
- NVAX United States
- Employees
- CUBI N/A
- NVAX N/A
- Industry
- CUBI Major Banks
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CUBI Finance
- NVAX Health Care
- Exchange
- CUBI Nasdaq
- NVAX Nasdaq
- Market Cap
- CUBI 1.4B
- NVAX 2.0B
- IPO Year
- CUBI 2012
- NVAX 1995
- Fundamental
- Price
- CUBI $46.46
- NVAX $9.76
- Analyst Decision
- CUBI Buy
- NVAX Buy
- Analyst Count
- CUBI 8
- NVAX 6
- Target Price
- CUBI $63.86
- NVAX $17.83
- AVG Volume (30 Days)
- CUBI 290.2K
- NVAX 7.2M
- Earning Date
- CUBI 10-31-2024
- NVAX 11-07-2024
- Dividend Yield
- CUBI N/A
- NVAX N/A
- EPS Growth
- CUBI 33.08
- NVAX N/A
- EPS
- CUBI 7.41
- NVAX N/A
- Revenue
- CUBI $722,462,000.00
- NVAX $987,667,000.00
- Revenue This Year
- CUBI N/A
- NVAX N/A
- Revenue Next Year
- CUBI $11.71
- NVAX N/A
- P/E Ratio
- CUBI $6.12
- NVAX N/A
- Revenue Growth
- CUBI 25.87
- NVAX N/A
- 52 Week Low
- CUBI $38.69
- NVAX $3.53
- 52 Week High
- CUBI $68.49
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- CUBI 48.18
- NVAX 36.20
- Support Level
- CUBI $44.31
- NVAX $9.52
- Resistance Level
- CUBI $47.11
- NVAX $10.63
- Average True Range (ATR)
- CUBI 1.57
- NVAX 0.57
- MACD
- CUBI 0.05
- NVAX -0.12
- Stochastic Oscillator
- CUBI 28.96
- NVAX 9.97
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources, and Financial Products and Services. The majority of revenue is derived from commercial lending.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.